GlassScriptPhysician profile
Nicole E Albert
NPI 1609188879
$10,437.56
in general payments reported to CMS, 2019-2025
36 companies · $2,272 in 2025
The $2,272 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $608 · 2021: $819 · 2022: $1,268 · 2023: $2,590 · 2024: $1,680 · 2025: $2,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,541.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,157.54 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,595.53 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $825.88 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $772.45 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $520.25 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $399.68 | 2019-2025 | |
| Gilead Sciences, INC. | $335.55 | 2019-2025 | Epclusa |
| Ardelyx, INC. | $313.98 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $299.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Cook Medical LLC | $240.52 | 2019-2023 | Hemospray |
| Intercept Pharmaceuticals, INC. | $206.37 | 2019-2024 | Ocaliva |
| Genzyme Corporation | $199.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.66 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $155.29 | 2021-2025 | Sucraid |
| Daiichi Sankyo INC. | $105.68 | 2019-2025 | Injectafer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $102.93 | 2024 | Voquezna |
| Stryker Corporation | $101.80 | 2025 | Axsos |
| Ucb, INC. | $99.44 | 2019-2020 | |
| Lilly USA, LLC | $87.98 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $86.67 | 2022 | |
| Merck Sharp & Dohme LLC | $79.64 | 2020-2024 | Dificid |
| Conmed Corporation | $79.49 | 2025 | Conmed Biliary |
| Ferring Pharmaceuticals INC. | $69.20 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $66.66 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $65.05 | 2022 | |
| Shire North American Group INC | $57.53 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $49.22 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $27.00 | 2019 | |
| Olympus America INC. | $25.76 | 2025 | Hanarostent Esophagus Tts(Ccc) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.22 | 2023 | Cyltezo |
| Amgen INC. | $20.29 | 2025 | Uplizna |
| Portola Pharmaceuticals, LLC | $19.02 | 2020 | |
| Aimmune Therapeutics, INC. | $18.02 | 2023 | |
| Redhill Biopharma INC. | $15.73 | 2023 | Movantik, Aemcolo, Talicia |
| Alfasigma USA, INC. | $15.47 | 2021 | |
| Dova Pharmaceuticals | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.